I didn't go looking for this theme, but funny enough my first article today is a mirror image of yesterday's last article......
Researchers at Ohio State have developed a new oncology therapeutic derived from the same chemical structure as Celebrex, which was previously noted to have an anti-cancer effect. The derivative compound (lead: OSU-03012) shares lineage with other COX-2 inhibitors.
It turns out the new compound and Celebrex inhibit Akt, which has long been a target of interest for pharma. (I don't know why prior Akt efforts have failed - was it toxicity? If, watch interest in Akt ramp up with the identification of safe Akt inhibitors based on COX-2 inhibitors.)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment